



**Company Contact:
Richard Gabriel
CEO and President
941 366-3400**

-or-

**Ron Stabiner
The Wall Street Group, Inc.
212-888-4848**

FOR IMMEDIATE RELEASE

**DNAPRINT GENOMICS' ANCESTRY TEST CAPABILITIES NOTED IN NEWSWEEK
COVER STORY**

SARASOTA, Fla., Feb. 3, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that the Company's AncestrybyDNA™ technology was cited in the cover story of this week's edition of *Newsweek* magazine in an article focusing on the growing use of DNA testing to understand family lineage and to answer questions about ancestry.

The magazine's cover for the edition dated February 6 featured the headline "Genes & Family/What Science Can Tell You About Your History And Your Health." The story on the inside was headlined "DNA Testing: In Our Blood," and went on to say that "History lives in our genes. The DNA in each of our cells not only dictates the color of our eyes, it also contains the footprints of our ancestors." The article also mentioned that DNAPrint Genomics specializes in DNA technology for determining a person's ancestry.

Newsweek focused on the growing popularity of DNA testing and how it is giving families surprising glimpses into their past. The author of the article, Claudia Kalb, who was assisted by contributing editor Karen Springen, took the AncestryByDNA™ tests offered by DNAPrint Genomics. After receiving the results of the tests, they expressed to DNAPrint Genomics their surprise about details of their ancestry that they did not expect.

The article also mentions Debra Anne Royer, a client of DNAPrint's Trace Genetics subsidiary, who discovered that her maternal ancestry was Native American, providing her important and satisfying knowledge since she was an adopted child. She had always wondered about her background because she often was asked if she were Iranian or Cambodian due to her darker skin and nose characteristics. *Newsweek* journalists interviewed three other clients of DNAPrint and its Trace Genetics subsidiary, all of whom expressed surprise at their newly founded knowledge about their ancestry.

The article noted that Trace Genetics has a large database of Native American DNA samples. Following publication of the article, DNA Print President and Chief Executive Office Richard Gabriel explained in a statement how this process works. "Native American individuals belong to one of five major maternal lineages or haplogroups, A, B, C, D or X," he explained. "If Trace Genetics'

(MORE)

Worldwide Ancestry-Mito test reveals that an individual belongs to one of the five Native American lineages, then we can run a Native American Mito Upgrade. The Mito Upgrade compares the client's mtDNA sequence against the Company's extensive Native American mtDNA database to identify geographic and tribal matches within the Americas."

Mr. Gabriel noted that there is no guarantee of a tribal match, but DNAPrint provides individuals information about whether their DNA is similar to those who claim to have tribal associations. "Having the DNA match does not prove that the client belongs to that tribe; it simply suggests the customer shares a distant common ancestor with individuals in the matched tribe and possibly non-sampled neighboring tribes," he said.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two new tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###